Nutlin-3

目录号:S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。

规格 价格 库存 购买数量  
RMB 1515.15 现货
RMB 900.36 现货
RMB 1407.13 现货
RMB 3026.07 现货
RMB 7939.67 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。
靶点
Mdm2 [5]
(Cell-free assay)
180 nM
体外研究

Nutlin-3有效抑制MDM2-p53相互作用,IC50 为 90 nM, 导致p53通路激活。Nutlin-3 处理含野生型p53的细胞,如HCT116, RKO 和SJSA-1,诱导MDM2 和p21表达, 且具有有效的抗增殖活性,IC50 为~1.5 μM, 但是作用于含突变型p53的细胞系 SW480和 MDA-MB-435没有效果。10 μM Nutlin-3处理 SJSA-1细胞48小时,显著诱导caspase依赖的细胞凋亡,凋亡达~45%。虽然Nutlin-3也抑制人皮肤 (1043SK) 和小鼠胚胎 (NIH/3T3) 的生长和活力,IC50分别为2.2 μM 和1.3 μM, 10 μM Nutlin-3处理一周后仍保留细胞活力,而3 μM Nutlin-3 处理SJSA-1细胞后,细胞则无活力。[1] Nutlin-3 不诱导p53在关键丝氨酸残基的磷酸化,在特定DNA结合序列没有区别,且与基因毒性药物Doxorubicin和Etoposide诱导的磷酸化p53相比, 使p53靶点基因转活,说明 p53 在关键丝氨酸残基的磷酸化对转录激活和凋亡是非必需的。[2] 虽然与MDM2相比,Nutlin-3 与MDMX 结合的效率低一点, Nutlin-3作用于视网膜母细胞瘤细胞(Weri1),能抑制MDMX–p53相互作用,且诱导 p53通路,IC50为0.7 μM。[3] 30 μM Nutlin-3作用于无野生型p53的细胞,也扰乱内源性p73-HDM2 相互作用,且增强p73稳定性和促凋亡活性, 导致细胞生长受抑制,和诱导凋亡。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[1xsDPxE1? NWH4Z2hWPDkEoHi= NFv2UYJjdG:la4OgNlcuV0iFLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHPvcZBiemGkbHWgeI8hfGijdDDv[kBj[XOjbDDs[ZZmdHN? NXnm[ZhROjZ|NUC1OlU>
NP69 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\zSo46UUN3ME2zNU43QcLzMj61OEDPxE1? NUjQRZppOjZ{NUK1O|U>
NP460 M2PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\jOYNKSzVyPUKyMlg2yrFzLkG4JO69VQ>? M{P6WFI3OjV{NUe1
C666-1 NXnKdYVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELHcZlKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? M2\QZ|I3OjV{NUe1
C666-1 M1zYTmNmdGxiVnnhZoltcXS7IFHzd4F6 NGjPOJAyOCEEtV2= MYi0PEBp MYXEUXNQ NWm2UZFIe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu NITDOXkzPjJ3MkW3OS=>
C666-1  M13WfGZ2dmO2aX;uJGF{e2G7 NWnjTItKOTBiwsXN M1O1U|I1KGh? NEXZRnZFVVOR MnnZZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z MnjUNlYzPTJ3N{W=
C666-1 NYfl[XZbSXCxcITvd4l{KEG|c3H5 NEfVW4IyOCEEtV2= MWq0PE84OiCq MWfEUXNQ MnL5d4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz NETnd28zPjJ3MkW3OS=>
A549 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkniNlQhcA>? MlzaTWM2OD1zNz62PEDDuSB2LkWyJO69VQ>? NXH3WnhuOjZzMkWyN|A>
A549-NTC M4W2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK3cJgzPCCq MlfVTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>? NWL6e5FEOjZzMkWyN|A>
A549-920 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzBe5czPCCq M4G0TmlEPTB;M{OuPFUhyrFiND64OEDPxE1? NGDVOZczPjF{NUKzNC=>
CRL-5908 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L1b|I1KGh? NFzJXm1KSzVyPUO4MlcyKMLzIEKuOFMh|ryP NX3UXGVyOjZzMkWyN|A>
L6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnk[VJHOTEEoN88UeKh MoXtNlQwPDhxN{KgbC=> NITIbJhFVVOR M37kTIlvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? Mlr5NlU5PzF5OUS=
C2C12 NWDTNGtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;qNVDDqM7:TdMg MWCyOE81QC95MjDo M4fSSWROW09? M4jC[olvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? M{m5RlI2QDdzN{m0
MCF-7  NFrvWVlHfW6ldHnvckBCe3OjeR?= NVq1[pU{OTEEoN88US=> MWfEUXNQ M3W5SIlvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? MoH3NlU4ODJ5MEO=
DU4475  M1jG[mZ2dmO2aX;uJGF{e2G7 M4jMT|UwOTBxMkCg{txO NHHkZ4MzPMLiaB?= NYq0SVlv\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>? NEH6TVMzPTV2N{G3OC=>
SMMC-7721 NGrBfolHfW6ldHnvckBCe3OjeR?= MYqxNEDPxE1? NX\lWopmPDhiaB?= NVPPUpRHTE2VTx?= MYnjZZV{\XNiRF7BJGRUSiCmYX3h[4U> NIHR[FgzPTV2NEO2NS=>
SMMC-7721 M3rQTWZ2dmO2aX;uJGF{e2G7 MUSxNEDPxE1? MVW0PEBp MUDEUXNQ NWTLfnIycW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NG\vZZkzPTV2NEO2NS=>
SMMC-7721 MlziSpVv[3Srb36gRZN{[Xl? MYGxNEDPxE1? MkLoOFghcA>? M1q1bGROW09? NG\0bJNqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3dCpGlHVkJzwrDtVm5C MkTMNlU2PDR|NkG=
SMMC-7721 MljCSpVv[3Srb36gRZN{[Xl? M3zpSlExKM7:TR?= M4HWRlM3KGh? NFTPZ2JFVVOR MoDhZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NHjyVY8zPTV2NEO2NS=>
MCF-7 NVLFT3hPTnWwY4Tpc44hSXO|YYm= M3O2OFExyqEQvF2= NUHnbow4OC1{NDDo NGLTXWJqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= M3TRWVI2PDh{M{ez
OVCAR10 M4\EWmZ2dmO2aX;uJGF{e2G7 NE\QRlkyOMLizszN Mo[2NlFpyqB? NU\IV5RiTE2VTx?= Mk\2bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NGXCPWkzPTR{NkW0PC=>
NCI-H23 MlK3SpVv[3Srb36gRZN{[Xl? Mn;INVDDqM7:TR?= MkS1NlFpyqB? NILqUWVFVVOR M4nlTolv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MoL2NlU1OjZ3NEi=
A2780 NGHFbXhHfW6ldHnvckBCe3OjeR?= NWDsUY1GOTEEoN88US=> Mn3ENlFpyqB? M2jtPGROW09? NVTz[VRTcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? M2n6OVI2PDJ4NUS4
NCI-H23 NYPTSlg4TnWwY4Tpc44hSXO|YYm= M1L1NFExyqEQvF2= M1\PZ|IycMLi M{jsSmROW09? MV7k[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MoDkNlU1OjZ3NEi=
A2780 M3v0dGZ2dmO2aX;uJGF{e2G7 MkPTNVDDqM7:TR?= MYeyNYjDqA>? NVfnOXp1TE2VTx?= M4LyboRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz NGP4eoQzPTR{NkW0PC=>
HCT116  MVvGeY5kfGmxbjDBd5NigQ>? NUPvc5ptOTBiwsXN M{HDZlI1KGh? M2GwR4NifXOnczDhJJA2Oy2mZYDlcoRmdnRidHX0doFxdG:rZDDHNU1ienKnc4SgbY4h\GmybH;p[EBJS1RzMU[gZ4xwdmW|IFSzJIFv\CCGOB?= M{PrWVI2OzhyMEW1
MCF-10CA1a M2XodmZ2dmO2aX;uJGF{e2G7 MU[xNOKh|ryP MmTzOFghcA>? MYLEUXNQ MonVbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? NFPYWIszPTJ3N{eyPS=>
MCF-10A1  M1HocGZ2dmO2aX;uJGF{e2G7 M4HlVFExyqEQvF2= M335WlI1NzR6IHi= MWfEUXNQ MV7pcohq[mm2czDtbYdz[XSrb36gc4Yhdm:{bXHsJIJz\WG|dDDldIl1cGWuaXHsxsA> M2XuSFI2OjV5N{K5
MCF-10CA1a MonOSpVv[3Srb36gRZN{[Xl? MWGxNOKh|ryP NVLCWJFwOjRiaB?= NVi5dY0{TE2VTx?= NX;RemN2\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= NUfvcGx2OjV{NUe3Nlk>
MCF-10CA1a NXjBcI92TnWwY4Tpc44hSXO|YYm= MYixNOKh|ryP NUDGSXVQOjRiaB?= M1rpe2ROW09? NUTEZoZicW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NH70SZkzPTJ3N{eyPS=>
SK-BR-7 M4DqeWZ2dmO2aX;uJGF{e2G7 Mkn6NVDDqM7:TR?= MX6yOEBp NEf4VmNFVVOR MmLFbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MorCNlUzPTd5Mkm=
SUM102PT NIHTUGdHfW6ldHnvckBCe3OjeR?= NH23VZUyOMLizszN NXzuXYNsOjRiaB?= Mo\5SG1UVw>? NGXIb|JqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MX:yOVI2Pzd{OR?=
RAW 264.7 MVPGeY5kfGmxbjDBd5NigQ>? NIjjOG8yOMLizszN MVOzNEBucW5? MVrwdoV3\W62czD0bIUheDV|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO= MWeyOVE4OjV2Nx?=
RAW 264.7 MlPhSpVv[3Srb36gRZN{[Xl? MYixNOKh|ryP NYrrbXlpOzBibXnu NUTw[o5XemWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=> NELFRm8zPTF5MkW0Oy=>
RAW 264.7 MWLGeY5kfGmxbjDBd5NigQ>? MmXTNVDDqM7:TR?= M4TENVMxKG2rbh?= M2HQfIlvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> NHn3d|EzPTF5MkW0Oy=>
MCF7  NF3ObWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWCyMlUhyrWP Mm\1OUBl M1nRZWROW09? MoDQd4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?= NHnMbmYzPTB6NUmwNi=>
MCF7  NGTQcWJHfW6ldHnvckBCe3OjeR?= M4HONlIvPSEEtV2= MmjaOFghcA>? NWXUTnRoTE2VTx?= MYDk[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> MUOyOVA5PTlyMh?=
ACHN MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mnf0NE42NTFyIN88US=> MUOwMVYh\A>? MX7EUXNQ NIriUWdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkHzNlUxPjd5OEe=
Caki-2 M2WzfWNmdGxiVnnhZoltcXS7IFHzd4F6 M4\YS|AvPS1zMDFOwG0> M4XVc|AuPiCm NGmzOJFFVVOR NHm4NWNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MojFNlUxPjd5OEe=
A498 NYLCbIpNS2WubDDWbYFjcWyrdImgRZN{[Xl? MkP3NE42NTFyIN88US=> NXTabWdXOC14IHS= MWHEUXNQ MkDMbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWHW[HlKOjVyNke3PFc>
115 NGfmU4JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVnMPIlOOC53LUGwJO69VQ>? MYCwMVYh\A>? NYixcJoyTE2VTx?= MnHqbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHPmbo8zPTB4N{e4Oy=>
117 M1n5VGNmdGxiVnnhZoltcXS7IFHzd4F6 NGPXOGoxNjVvMUCg{txO NXvBS3N4OC14IHS= M33VXGROW09? Ml\QbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2Tu[VI2ODZ5N{i3
ACHN M2\3OmZ2dmO2aX;uJGF{e2G7 NG\6RlcxNjVxMT:1JO69VQ>? NIjvWoc1QCCq NH;uTXZFVVOR M3f3NIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NXLZWIxDOjVyNke3PFc>
Caki-2 NG\sdnZHfW6ldHnvckBCe3OjeR?= NIXBXlkxNjVxMT:1JO69VQ>? NIHDRmk1QCCq MXXEUXNQ MUDs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? Mm[0NlUxPjd5OEe=
A498 MmO0SpVv[3Srb36gRZN{[Xl? MUCwMlUwOS93IN88US=> M{S3PFQ5KGh? NXr6dGQ1TE2VTx?= MmrBcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M3nEUFI2ODZ5N{i3
115 MYjGeY5kfGmxbjDBd5NigQ>? NYDGOFc5OC53L{GvOUDPxE1? NEmxNWs1QCCq NVXrcox2TE2VTx?= NILWWoFt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MnjvNlUxPjd5OEe=
ACHN M4HhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTCOUDPxE1? MnfJOFghcA>? NXe0fWdwTE2VTx?= M{n2Uolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NVHTdFA1OjVyNke3PFc>
Caki-2 M2PpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomzOUDPxE1? M3PnVlQ5KGh? MUHEUXNQ MUPpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NGOxenYzPTB4N{e4Oy=>
A498 NXuydFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW5dFg2KM7:TR?= MlLBOFghcA>? MV7EUXNQ M{\6Solv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NELETnozPTB4N{e4Oy=>
115 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnUOUDPxE1? NVfFVXJvPDhiaB?= MVvEUXNQ NEX0OmpqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MoT0NlUxPjd5OEe=
ACHN NX:3R2VRTnWwY4Tpc44hSXO|YYm= MVG1JO69VQ>? NXLtdohZPDhiaB?= MX3EUXNQ MoPKbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NFjz[3IzPTB4N{e4Oy=>
Caki-2 MUDGeY5kfGmxbjDBd5NigQ>? MUW1JO69VQ>? MoXBOFghcA>? M3q5O2ROW09? NYq5cpA6cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NF\tdnUzPTB4N{e4Oy=>
A498 M3u1UGZ2dmO2aX;uJGF{e2G7 MUS1JO69VQ>? M33Md|Q5KGh? MXHEUXNQ NFizco1qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg Ml3lNlUxPjd5OEe=
115 NX\QN|JITnWwY4Tpc44hSXO|YYm= M1vobVUh|ryP NVLISWtCPDhiaB?= MmLiSG1UVw>? NFXHUItqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M2K3cFI2ODZ5N{i3
MOLM-13 MX3GeY5kfGmxbjDBd5NigQ>? M2n6[|bDqM7:TR?= MXywMVghcA>? MlrYSG1UVw>? M2Kx[Ylv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? MX2yOFg5PTB6Mh?=
MOLM-13 NIXrN5lHfW6ldHnvckBCe3OjeR?= M1[5WlbDqM7:TR?= M3f1NlYhcA>? M4n2UGROW09? M1PMRoVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= MnvCNlQ5QDVyOEK=
HepG2 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[3NkBp NWXCTFB{TE2VTx?= MUfJR|UxRTN3Lki2JOKyKDJwOTFOwG0> MU[yOFg5PDhyOR?=
HepG2/As M2DQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPpO|IhcA>? MVvEUXNQ NYf5PZZUUUN3ME22PE4yOyEEsTC5MlYh|ryP Ml\4NlQ5QDR6MEm=
SMMC7721 NVu1[FVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\iT|czKGh? M{LjemROW09? MoS2TWM2OD1|MT6yPEDDuSB2LkKg{txO MXyyOFg5PDhyOR?=
SMMC7721/Ac MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjvVYhUPzJiaB?= Mn\NSG1UVw>? M37jXWlEPTB;NUWuNlEhyrFiNT6wN{DPxE1? MXyyOFg5PDhyOR?=
Huh-7 NWXVUFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSzO|IhcA>? MXvEUXNQ MmLmTWM2OD1|Mz65OkDDuSB|Lkmg{txO NETleGMzPDh6NEiwPS=>
Hep3B NVztR4tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fjR|czKGh? M4nRdWROW09? M{T3XmlEPTB;MkCuNVghyrFiMT64OEDPxE1? Mk\tNlQ5QDR6MEm=
HepG2 MoDiRZBweHSxc3nzJGF{e2G7 Ml\YbY5lfWOnczDhdI9xfG:|aYO= NIWwN2UzPDh6NEiwPS=>
SMMC7721 NX3FVIo3SXCxcITvd4l{KEG|c3H5 MWLpcoR2[2W|IHHwc5B1d3Orcx?= MlH5NlQ5QDR6MEm=
Huh-7 NFzsdW5CeG:ydH;zbZMhSXO|YYm= MoDhbY5lfWOnczDhdI9xfG:|aYO= NH3YfmgzPDh6NEiwPS=>
Hep3B NHS1OWxCeG:ydH;zbZMhSXO|YYm= NXXueod3cW6mdXPld{BieG:ydH;zbZM> MoH2NlQ5QDR6MEm=
U2OS  NVj5VI1KTnWwY4Tpc44hSXO|YYm= NX7lbJVHOjBizszN NHrnXFkzPCCq MXjpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ MXWyOFg3PzJ3OR?=
AML2 MnTCRZBweHSxc3nzJGF{e2G7 Ml3ZNk8yOCEQvF2= NEn1foYzPC92ODDo MkjJbY5lfWOnczDhdI9xfG:|aYO= MnTRNlQ3PTl5NEm=
MOML13 MUTBdI9xfG:|aYOgRZN{[Xl? MoTKNk8yOCEQvF2= NVXMSVNyOjRxNEigbC=> MXfpcoR2[2W|IHHwc5B1d3Orcx?= NV22VHY3OjR4NUm3OFk>
AML2 NWftTYJ3TnWwY4Tpc44hSXO|YYm= Ml\lNVDPxE1? MofGNk81KGh? MljCbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MVqyOFY2QTd2OR?=
AML3 MW\GeY5kfGmxbjDBd5NigQ>? NXLLPJhSOTEQvF2= NIXnUYMzNzRiaB?= NWjUW3E5cW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NES4WJkzPDZ3OUe0PS=>
MOML13 MYnGeY5kfGmxbjDBd5NigQ>? MlHyNVDPxE1? M1SzO|IwPCCq NXvlTnlIcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NEjrUYwzPDZ3OUe0PS=>
BeWo NV7MUpU{TnWwY4Tpc44hSXO|YYm= NHPhbZE{OCEEtV2= MmTiNlQhcA>? NV33U3dmcW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVt MYmyOFQ6QDF3NB?=
BeWo MXTBdI9xfG:|aYOgRZN{[Xl? NYXVRoJyOzBiwsXN NEHkZpgzPCCq M122bYlv[3KnYYPld{BieG:ydH;zbZM> MVSyOFQ6QDF3NB?=
OCI MYTGeY5kfGmxbjDBd5NigQ>? M{LzS|ExKM7:TR?= NIXqZ4QzPCCq MoWzeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MVqyOFQ4OzV4Mh?=
MOLM MoDrSpVv[3Srb36gRZN{[Xl? NYK3W49bOTBizszN NVnHR|ExOjRiaB?= Mlj4eZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w NUGxSHMzOjR2N{O1OlI>
U2OS  Mk\RSpVv[3Srb36gRZN{[Xl? M4rYblIxKM7:TR?= M4KzfVI1KGh? NFr3SHhqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NVTuU4ozOjR|Nk[wNFc>
RKO NXLq[WM{TnWwY4Tpc44hSXO|YYm= M4GwbVIxKM7:TR?= NV34Z3RzOjRiaB?= NWm2bJlicW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MnH6NlQ{PjZyMEe=
U2OS  MUHGeY5kfGmxbjDBd5NigQ>? NXvrUVNwOjBizszN M{\VW|I1KGh? NYP0ZWM{cW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MUmyOFM3PjByNx?=
RKO M4Hnb2Z2dmO2aX;uJGF{e2G7 NFXGUmMzOCEQvF2= NGrnbWMzPCCq MVrpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NFnJd2czPDN4NkCwOy=>
SMMC-7721  NEDRWYlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmCwNU4zPS1{MDFOwG0> NEH1W|kzPC92OD:3NkBp NEDQUJZFVVOR NIf4XVBqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> M1nmfVI1Ojh4M{Gy
HuH-7 NFzG[otE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmrTNU4zPS1{MDFOwG0> NFfSW3QzPC92OD:3NkBp MXTEUXNQ MnPDbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NWfLdmp1OjR{OE[zNVI>
SMMC-7721  NWn3SG1sSXCxcITvd4l{KEG|c3H5 Mni1NlAh|ryP NV7Tb3lFPDhiaB?= MVnEUXNQ NXXTUolscW6mdXPld{BieG:ydH;zbZM> M1fXVVI1Ojh4M{Gy
HuH-7 M1mxSmFxd3C2b4Ppd{BCe3OjeR?= NF3MeJgzOCEQvF2= NFjyO|k1QCCq NILw[YFFVVOR M4XWb4lv\HWlZYOgZZBweHSxc3nz MX[yOFI5PjNzMh?=
SMMC-7721  NYLlbnlQTnWwY4Tpc44hSXO|YYm= MVyxNEDPxE1? NHvQVHk{PiCq MUTEUXNQ Monv[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> NVvLTploOjR{OE[zNVI>
HuH-7 MnTDSpVv[3Srb36gRZN{[Xl? NF7jPGMyOCEQvF2= MVmzOkBp M3\ifWROW09? M4PrV4Rwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ M4TCfVI1Ojh4M{Gy
AT2 MWnGeY5kfGmxbjDBd5NigQ>? MVG1M|ExKM7:TR?= M2DNU4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NFX1OIszPDJ2MEKwNy=>
REH M1TaNGZ2dmO2aX;uJGF{e2G7 Mlz5OU8yOCEQvF2= MV\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? M3;BR|I1OjRyMkCz
UoCB6 NYXWVndLTnWwY4Tpc44hSXO|YYm= NFXvXHk2NzFyIN88US=> MU\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? M3S0VlI1OjRyMkCz
AT2 NEfBOHpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NULmcIVMOC1{NTFOwG0> M3jzWYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NHvDNmkzPDJ2MEKwNy=>
REH M2DHU2NmdGxiVnnhZoltcXS7IFHzd4F6 NVHyWZBVOC1{NTFOwG0> MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NEXvUI8zPDJ2MEKwNy=>
UoCB6 NF\zO5ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXWx[JNQOC1{NTFOwG0> NE[wclFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NH32PYYzPDJ2MEKwNy=>
A2780 M4P4d2Z2dmO2aX;uJGF{e2G7 NVq1RmdTPS9zMD:yNEDPxE1? NXLGPFBEOjRiaB?= MWL1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? M1vNW|I1OTN4MUS3
H460 Ml36SpVv[3Srb36gRZN{[Xl? MWW1M|ExNzJyIN88US=> NHizd|YzPCCq MVH1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? M2i2T|I1OTN4MUS3
Lovo  MlewSpVv[3Srb36gRZN{[Xl? M1;TN|UwOTBxMkCg{txO NGH2NpQzPCCq M4TsZ5VxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NGrweXczPDF|NkG0Oy=>
A2780 MXXBdI9xfG:|aYOgRZN{[Xl? MUW1M|ExNzJyIN88US=> NXjVNndrOjRiaB?= NUfNN4tl\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M3TKUVI1OTN4MUS3
H460 MmHkRZBweHSxc3nzJGF{e2G7 M2XqcFUwOTBxMkCg{txO NITDNmQzPCCq NXPxNI1b\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M1K2clI1OTN4MUS3
Lovo  MUTBdI9xfG:|aYOgRZN{[Xl? NGHVNI02NzFyL{KwJO69VQ>? MVuyOEBp NITwZ2RmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NY[3fVhVOjRzM{[xOFc>

... Click to View More Cell Line Experimental Data

体内研究 Nutlin-3 按200 mg/kg 剂量口服处理,每天两次,持续3周,显著抑制SJAS-1移植瘤生长,抑制达90%, 而Doxorubicin抑制81%肿瘤生长。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Biacore 研究:

在Biacore S51上进行竞争性实验。衍生一系列S传感器芯片CM5,用于固定 PentaHis抗体,为了捕获 His-标记的p53。捕获的水平为~200反应单位(1 反应单位对应于1 pg 蛋白/ mm2)。MDM2蛋白浓度一直维持在300 nM。Nutlin-3 溶于DMSO,浓度为10 mM,然后进一步稀释,在每个MDM2实验样本中产生系列浓度的Nutlin-3。在电泳缓冲液(10 mM Hepes,0.15 M NaCl, 2% DMSO)中25oC下进行实验。在Nutlin-3存在时,计算MDM2-p53结合情况,作为结合百分数, 使用Microsoft Excel计算IC50。
细胞实验:

[1]

+ 展开
  • Cell lines: HCT116, RKO, SJSA-1, SW480, 和 MDA-MB-435
  • Concentrations: 溶于DMSO,终浓度为~ 30 μM
  • Incubation Time: 8, 24, 和 48 小时
  • Method:

    使用不同浓度Nutlin-3处理细胞8, 24和 48 小时。通过实时PCR分析p21 和MDM2基因转录水平,通过Western Blotting分析蛋白水平。通过MTT实验测定细胞活力。 通过末端脱氧核苷酸转移酶调节的脱氧尿苷三磷酸缺口末端标记法(TUNEL)染色,使用流式细胞仪和荧光显微镜测定细胞凋亡。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 皮下注射 SJSA-1细胞的雌性无胸腺Nu/Nu-nuBR裸鼠
  • Formulation: 在 2% Klucel, 0.5% Tween-80配制中配制
  • Dosages: 200 mg/kg
  • Administration: 口服处理,每天两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.5
化学式

C30H30Cl2N4O4

CAS号 890090-75-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3 | Nutlin-3供应商 | 采购Nutlin-3 | Nutlin-3价格 | Nutlin-3生产 | 订购Nutlin-3 | Nutlin-3代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID